Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Deleuze, FR
Anne-Laure Deleuze, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20090147831 | METHOD OF MULTIPLE ACCESS COMMUNICATION IN A CENTRALIZED NETWORK BASED ON AN ULTRA WIDEBAND IMPULSE PHYSICAL LAYER - Method of multiple access communication in a centralized network based on an ultra wideband impulse physical layer allowing code-based multiple access, each user being associated with a code, the transmission being performed in an asynchronous manner in a propagation medium with multiple paths. It is characterized in that a criterion is established so as to find the codes of the Nu various users making it possible to minimize the variance of the multi-user interference J | 06-11-2009 |
Charles Deleuze, Monts FR
| Patent application number | Description | Published |
|---|---|---|
| 20090266823 | METHOD FOR MANUFACTURING A SEALING BLADDER MADE OF THERMOSETTING POLYMER FOR A TANK CONTAINING A PRESSURIZED FLUID, SUCH AS A COMPOSITE TANK, AND A TANK - A method for manufacturing a polymer bladder assuring the internal sealing of a tank vis-à-vis a pressurized fluid which is contained therein, wherein said polymer is a thermosetting polymer, and said method comprises at least one step of polymerizing at least two precursor compounds of said thermosetting polymer carried out in a mould in rotation. | 10-29-2009 |
Herve Deleuze, Saint Magne FR
| Patent application number | Description | Published |
|---|---|---|
| 20110130534 | HIGH-STRENGTH POLYHIPE MATERIAL, PROCESS FOR PREPARING THE SAME, EMULSION USEFUL FOR PREPARATION THEREOF AND ARTICLE FORMED OF SAID MATERIAL - The invention relates to a polyHIPE material provided with high mechanical strength, which material comprises at least one N-alkenyltriazole monomer and a cross-linking monomer in a weight ratio of cross-linking monomer/N-alkenyltriazole monomer of 1/100 to 60/100. | 06-02-2011 |
Hervé Deleuze, Le Barp FR
| Patent application number | Description | Published |
|---|---|---|
| 20100166930 | PROCESS FOR EXTRACTING CARBONYLATED COMPOUNDS FROM A DRINK BY LIQUID-SOLID EXTRACTION WITH A FUNCTIONALIZED INERT SUPPORT - The present invention relates to a process for extracting carbonylated compounds from a drink by liquid-solid extraction with a functionalized inert support containing nitrogenous nucleophilic functional groups. Advantageously, according to the present invention, the drink is wine or fruit juice. The process according to the present invention is advantageously applied to the reduction of the sulphur dioxide combination capacity of a drink such as wine. | 07-01-2010 |
Hervé Deleuze, Le Barp FR
| Patent application number | Description | Published |
|---|---|---|
| 20100166930 | PROCESS FOR EXTRACTING CARBONYLATED COMPOUNDS FROM A DRINK BY LIQUID-SOLID EXTRACTION WITH A FUNCTIONALIZED INERT SUPPORT - The present invention relates to a process for extracting carbonylated compounds from a drink by liquid-solid extraction with a functionalized inert support containing nitrogenous nucleophilic functional groups. Advantageously, according to the present invention, the drink is wine or fruit juice. The process according to the present invention is advantageously applied to the reduction of the sulphur dioxide combination capacity of a drink such as wine. | 07-01-2010 |
Jean-Francois Deleuze, Combs La Ville FR
| Patent application number | Description | Published |
|---|---|---|
| 20090239237 | METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM - The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism. | 09-24-2009 |
| 20100062431 | USE OF ADAMTS4 GENE AND PROTEIN POLYMORPHISMS - The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so. | 03-11-2010 |
| 20100221714 | ANALYSIS AND USE OF PAR1 POLYMORPHISMS FOR EVALUATING THE RISK OF CARDIOVASCULAR DISEASE - The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis. | 09-02-2010 |
| 20100221738 | METHOD OF DIAGNOSIS OF A PREDISPOSITION TO DEVELOP THROMBOTIC DISEASE AND ITS USES - The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P | 09-02-2010 |
| 20110104704 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF - The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject. | 05-05-2011 |
Jean-Francois Deleuze, Evry FR
| Patent application number | Description | Published |
|---|---|---|
| 20080312098 | Use of a Gip Promoter Polymorphism - The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined. | 12-18-2008 |